Effect of Acupoint Liquid Nitrogen Cryotherapy on Neuro-Endocrine-Immune Network System in Patients with Lung Qi Deficiency Syndrome in Remission Stage of Bronchial Asthma

[Objectives]To observe the effect of acupoint liquid nitrogen cryotherapy on the neuro-endocrine-immune network system of lung qi deficiency syndrome during the remission period of bronchial asthma and explore its possible mechanism.[Methods]A total of 100 patients with bronchial asthma were randomly divided into control group and observation group,with 50 cases in each group.The control group was given budesonide spray inhalation treatment,combined with acupoint liquid nitrogen freezing treatment,twice a year for a course of treatment,followed up for 1 year.The other 50 healthy volunteers were included in the healthy group,and no treatment was given in the healthy group.Serum immunoglobulins A,G,E(IgA,IgG,IgE)were detected before and after treatment in each group,serum cytokines[interleukin-4(IL-4),interleukin-10(IL-10),tumor necrosis factor-α(TNF-α),interferon-γ(IFN-γ)],plasma neurotransmitters[substance P(SP),vasoactive intestinal peptide(VIP)].[Results]Before treatment,compared with healthy group,the contents of IgA,IgG,IL-10,IFN-γand VIP in observation group and control group were decreased,while the contents of IgE,IL-4,TNF-αand SP were increased,with statistical significance(P<0.05).After treatment,compared with before treatment,IgA,IgG,IL-10,IFN-γand VIP contents in observation group and control group were increased(P<0.05),and observation group was higher than control group(P<0.05),IgE,IL-4 and SP contents in observation group and control group were decreased(P<0.05).The observation group was lower than the control group(P<0.05).[Conclusions]Acupoint liquid nitrogen cryotherapy may improve the immune function of the body,regulate the release of cytokines and regulate neuromediators,and thus play a role in the prevention and treatment of bronchial asthma.

CLINICAL OBSERVATION ON TREATMENT OF ALLERGIC BRONCHIAL ASTHMA WITH ACUPOINT APPLICATION THERAPY

In the present paper, the therapeutic effect of acupoint application of Chinese Materia Medica in the treatment of allergic asthma was observed. The results revealed that topical application of drug paste [mixture of powder of Mahuang (Herba Ephedrae), Xixin (Herba Asari), Baijiezi (Semen Sinapis Albae), etc.] at the acupuncture points could improve symptoms and signs of allergic asthma patients, with the total effective rate being 69.57% (16/23) for the short term effect, and 52.17%(12/23) for the long term effect. In medication (Aminophylline) group, of the 25 cases of allergic asthma, 16 (64.0%) were effective after 4 weeks of treatment, while 6 (24.0%) were still effective that was shown by 6 months’ follow up. The therapeutic effect of acupoint application group was significantly better than that of medication group in the long term effect. Results also showed that no obvious interrelation between the short term therapeutic effect and the duration or the severity of the disease. Results also display that acupoint application therapy is an effective, safe and handy method with fewer side effects for asthma.

Analysis of the Effect of Non-Invasive Positive Pressure Ventilation in Emergency Treatment of Severe Bronchial Asthma with Respiratory Failure

Objective:This study aims to evaluate the clinical efficacy of non-invasive positive pressure ventilation(NIPPV)in patients with severe bronchial asthma combined with respiratory failure.Methods:90 patients with severe bronchial asthma combined with respiratory failure between September 2022 and December 2023 were selected for the study and randomly divided into the experimental group(NIPPV-assisted treatment)and the control group.The differences between the two groups were compared in terms of total effective rate of treatment,days of clinical symptom disappearance,days of hospitalization,lung function indexes,incidence of adverse reactions,and quality of life.Results:Patients in the experimental group had a significantly higher total effective rate of treatment(97.78%)than the control group(75.56%).In terms of pulmonary function indexes,patients in the experimental group showed significant improvement after treatment,especially the increase in forced expiratory volume and forced vital capacity,while these improvements were not as obvious in the control group.In addition,the incidence of adverse reactions was significantly lower in the experimental group than in the control group,suggesting that the application of NIPPV is relatively safe.Quality of life assessment also showed that patients in the experimental group had significantly better quality of life than the control group after treatment.Conclusion:This study demonstrated the effectiveness of NIPPV as an adjunctive treatment for severe bronchial asthma combined with respiratory failure.NIPPV can improve lung function,reduce the incidence of adverse effects,increase the overall effectiveness of the treatment,and contribute to the improvement of patients'quality of life.Therefore,NIPPV should be regarded as an effective and safe treatment in clinical management,especially in patients with severe bronchial asthma combined with respiratory failure,where its application has potential clinical significance.

Remission of bronchial asthma after viral clearance in chronic hepatitis C

A 53-year-old man with a history of blood transfusion at the age of 20 was admitted to our hospital because of liver dysfunction. He had bronchial asthma when he was 18 years old, which naturally resolved within 2 years. However, his bronchial asthma recurred at the age of 45 and was treated with oral theophylline. He was diagnosed as having chronic hepatitis C based on the histological and clinical findings, and then interferon (IFN) therapy was administered. The frequency of bronchial asthma attack was gradually decreasing after IFN therapy with marked improvement of hypereosinophilia. He achieved sustained viral response (SVR) and his bronchial asthma did not worsen even after the cessation of IFN. Hepatitis C virus (HCV) infection and IFN therapy were considered in the remission of asthma in this case. HCV infection could be the cause of bronchial asthma, especially in patients with late appearance of asthma.

OBSERVATION ON THE THERAPEUTIC EFFECT OF ACUPOINT APPLICATION OF FAR-INFRARED ASTHMA-RELIEVING PLASTER FOR ASTHMA

Objective To observe the clinical effect of acupoint application of Yuanhongwai Xiaochuankang Plaster （Far-infrared Asthma-relieving Plaster, FIRARP） for prevention and treatment of asthma. Methods Three hundred and sixty-six cases of bronchial asthma were randomly divided into treatment group （n = 185） and control group （n = 181 ）. Patients of treatment group were treated with FIRARP and those of control group treated with external application of traditional ＂Sonfu （Dog-days） moxibustion＂ （herbal-paste-cake separated moxibustion） and acupoints used were Dazhui（大椎 GV14）, Feishu（肺俞BL13）, Tiantu （天突 CV22）, etc. which were given to the patients. Forced expiratory volume in 1 second （FEV1） and peak expiratory flow （PEF） of the pulmonary function were determined and the changes of main symptoms and signs were observed before and after the treatment. Results The pulmonary functions were effectively improved, the symptoms were controlled, and the asthma attack was reduced in the two groups with no significant difference between the two groups （P 〉0.05）. Conclusion There is no significant difference between Yuanhongwai Xiaochuonkong Plaster and traditional ＂Sanfu moxibustion＂ on bronchial asthma. It may substitute for traditional ＂Sonfu moxibustion＂.

2型炎症型支气管哮喘的生物靶向治疗

支气管哮喘是由多种炎症细胞及细胞因子参与的气道慢性炎症性疾病。重度哮喘表现为反复发作、迁延不愈,咳嗽、胸闷、气短、喘憋等症状较难缓解,对患者的生活质量造成重大的影响。目前标准治疗为吸入大剂量皮质类固醇联合长效支气管舒张剂,但仍有部分患者哮喘症状不能得到充分控制,往往与持续性2型炎症有关。对于持续性2型炎症的重度哮喘患者,可选择使用生物靶向药物治疗。生物靶向药物治疗可显著改善症状,降低急性加重频率,减少口服糖皮质激素的使用,为2型炎症型重度哮喘患者带来了新的希望,在此文章对2型炎症型支气管哮喘的生物靶向治疗进行综述。

健脾益气平喘方联合冬病夏治之穴位敷贴对缓解期支气管哮喘(肺气虚证)患者的作用效果

目的 探究健脾益气平喘方联合冬病夏治之穴位敷贴对缓解期支气管哮喘(肺气虚证)患者的作用效果。方法 以随机数字表法将安阳市中医院在2019年3月至2020年3月收治的110例缓解期支气管哮喘(肺气虚证)患者分为两组,接受冬病夏治之穴位敷贴治疗为对照组,接受健脾益气平喘方联合冬病夏治之穴位敷贴治疗为观察组,每组55例,3 a为1个治疗周期。比较两组临床疗效,治疗前后中医证候评分、血液流变学水平、免疫功能[γ干扰素(IFN-γ)、免疫球蛋白(IgE)、白细胞介素(IL)-4]以及抗氧化[超氧化物歧化酶(SOD)、丙二醛(MDA)、谷胱甘肽过氧化物酶(GSH-Px)]水平。结果 观察组总有效率高于对照组(P<0.05);与治疗前比,治疗后两组中医证候评分均下降,观察组比对照组低(P<0.05);与治疗前比,治疗后两组高切、中切、低切全血黏度均下降,观察组比对照组低(P<0.05);与治疗前比,治疗后两组IL-4、IgE、MDA水平均下降,观察组比对照组低;IFN-γ、SOD、GSH-Px水平上升,观察组比对照组高(P<0.05)。结论 健脾益气平喘方联合冬病夏治之穴位敷贴治疗用于缓解期支气管哮喘(肺气虚证)患者,能够改善患者生活质量,缓解临床症状,改善机体微循环,调节免疫功能,提高机体抗氧化能力。

全程优质护理服务对小儿支气管哮喘雾化吸入的作用效果

目的观察在雾化吸入治疗支气管哮喘患儿中施以全程优质护理服务的效果。方法选择于2022年6月至2023年5月就诊于河南省儿童医院的90例支气管哮喘患儿为观察对象,治疗方法均为雾化吸入治疗,按照随机数字表法分为试验组和对照组,其中45例接受全程优质护理服务的患儿为试验组,45例接受常规护理的患儿为对照组,并对护理效果、护理满意度、肺功能指标、治疗时间、治疗依从性进行观察和对比。结果试验组护理效果(97.78%)优于对照组患儿(82.22%)(P<0.05);试验组护理满意度(97.78%)高于对照组(80.00%)(P<0.05);试验组护理后肺功能指标优于对照组(P<0.05)。试验组咳嗽、喘息消失时间和住院时间较对照组短(P<0.05)。试验组患儿治疗依从性(95.56%)优于对照组(73.33%)(P<0.05)。结论对运用雾化吸入治疗的支气管哮喘患儿施以全程优质护理可提高护理效果及满意度,改善患儿肺功能指标,缩短咳嗽、喘息消失时间和住院时间,促进治疗依从性提升,值得推广。

图画互动式教育模式对雾化治疗支气管哮喘患儿心理状态及治疗依从性的影响

目的:探讨图画互动式教育模式对支气管哮喘儿童雾化治疗的心理状态和治疗依从性的影响。方法:对2023年1月—2024年1月于某院确诊患有支气管哮喘并正在接受雾化治疗的85例支气管哮喘患儿进行随机对照试验,在对两组患儿入院后进行常规治疗的基础上,参与者被分为两组接受为期4周的干预护理,干预组接受图画互动式教育干预护理,对照组仅接受常规护理;通过标准化问卷和医院自制的评分表对患儿的哮喘控制效果、治疗依从性、心理状态、生活质量、家属护理满意度进行评估比较。结果:图画互动式教育模式干预后,与对照组相比,干预组患儿的哮喘总控制率显著升高(χ^(2)=5.308,P<0.05);接受图画互动教育模式的患儿治疗依从性更高(P<0.05);干预组患儿的心理状态显著高于对照组(t=5.049,3.666,4.459,3.810;P<0.001);干预组患儿的生活质量较对照组显著提升(t=5.907,3.819,4.361;P<0.001);干预组患儿家属的护理满意度较对照组有明显改善(χ^(2)=5.308,P<0.05)。结论:对支气管哮喘患儿进行图画互动式教育模式的护理干预,可以有效提升哮喘控制率、治疗依从性和家属护理满意度,有助于患儿心理状态的纠正,从而提高生活质量。

重度哮喘诊治新进展

重度哮喘在总体哮喘人群中占比为5%~10%,导致患者生活质量显著下降、医疗支出明显增加。尽管目前对重度哮喘患者给予高剂量吸入性糖皮质激素联合长效β_(2)受体激动剂或口服糖皮质激素治疗,但仍有部分患者难以控制症状,且长期大量使用激素会带来许多不良反应。近年来针对重度哮喘的诊断和治疗手段不断进步,为临床应用提供了很多新选择。本文就重度哮喘的病情评估、生物制剂治疗、经支气管镜介入治疗等方面的研究进展进行综述。

穴位贴敷联合中药治疗支气管哮喘急性发作期的疗效观察

目的观察白芥子散穴位贴敷联合麻龙定喘汤治疗支气管哮喘急性发作期的临床疗效。方法选取支气管哮喘急性发作期患者80例,随机分为研究组和对照组,每组40例。两组均予常规治疗,对照组采用口服麻龙定喘汤治疗,研究组在对照组基础上联合白芥子散穴位贴敷治疗。比较两组临床疗效和不良反应发生情况,观察两组治疗前后中医证候积分、肺功能指标、血清转化生长因子β1(transforming growth factor-β1,TGF-β1)和基质金属蛋白酶-9(matrix metalloproteinase-9,MMP-9)水平的变化。结果研究组总有效率和显效率均高于对照组(P<0.05)。治疗后,研究组中医证候积分低于对照组(P<0.05),研究组用力肺活量(forced vital capacity,FVC)、呼气峰值流速(peak expiratory flow,PEF)及第一秒最大呼气容积(forced expiratory volume in 1 second,FEV1)均高于对照组(P<0.05),研究组血清TGF-β1和MMP-9水平均低于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论在常规治疗基础上,白芥子散穴位贴敷联合麻龙定喘汤治疗能减轻支气管哮喘发作期患者咳嗽、喘息等临床症状,改善肺功能,减轻炎症反应,疗效优于单一中药治疗。

中医护理技术配合穴位敷贴对支气管哮喘缓解肺功能及不良反应的影响

目的研究中医护理技术配合穴位敷贴对支气管哮喘对缓解患者肺功能水平,降低不良反应的影响。方法我院2020年5月至2023年7月收治支气管哮喘患者70例,通过双盲法分成两组,各35例。对照组实施常规护理,观察组实施中医护理技术+穴位敷贴,比较两组干预1个月后,干预效果、肺功能的改善情况及发生的不良反应情况。结果观察组相较于对照组,总有效率更高,不良情绪改善更显著,肺部症状消失时间更短,肺功能各指标改善更显著,生活质量提升更显著,不良反应率更低,组间比较有统计学意义(P<0.05)。结论支气管哮喘患者临床治疗过程中,通过中医护理配合穴位敷贴的技术支持,可以缓解患者的肺功能水平,提升患者生活质量同时,也能有效降低不良反应率发生,确保患者临床治疗的安全性,适于临床推广。

穴位推拿联合布地奈德+特布他林雾化吸入治疗支气管哮喘患儿的效果及对炎症因子水平的影响

目的探讨穴位推拿联合布地奈德+特布他林雾化吸入治疗支气管哮喘患儿的效果及对炎症因子水平的影响。方法选取2021年1月至2022年1月收治的64例支气管哮喘患儿,采用随机数字表法将其分为A组(32例,布地奈德+特布他林雾化吸入治疗)和B组(32例,在A组基础上实施穴位推拿)。比较两组的治疗效果。结果治疗后,两组的喘息、呼吸困难、咳嗽及肺部湿啰音评分降低,且B组低于A组(P<0.05)。治疗后,两组的儿童哮喘控制测试问卷(C-ACT)评分、第1秒用力呼气容积占预计值的百分比(FEV1%)、最大呼气峰流速度占预计值的百分比(PEF%)高于治疗前(P<0.05);治疗后,B组的C-ACT评分、FEV1%和PEF%高于A组(P<0.05)。治疗后,两组的嗜酸性粒细胞(EOS)计数及免疫球蛋白E(IgE)、神经营养因子-3(NT-3)水平低于治疗前(P<0.05);治疗后,B组的EOS计数及IgE、NT-3水平低于A组(P<0.05)。随访6个月,两组的哮喘复发率无显著差异(P>0.05)。结论穴位推拿联合布地奈德+特布他林雾化吸入治疗支气管哮喘患儿的效果显著,可改善临床症状和肺功能,降低炎症因子水平,值得临床推广应用。

针刺治疗支气管哮喘临床观察

目的探讨采用针刺治疗支气管哮喘的效果。方法选择南昌市洪都中医院2020年6月—2021年6月收治的68例支气管哮喘患者作为研究对象,按随机数字表法将其随机分为对照组和观察组,每组34例。对照组采用西医疗法,观察组在对照组的基础上施行中医针刺疗法。分析对比2组患者的肺功能[用力肺活量(FVC)、第1秒用力呼气容积(FEV_(1))、一秒率(FEV_(1)/FVC)]和治疗总有效率。结果治疗后,观察组的FVC、FEV_(1)、FEV_(1)/FVC水平均高于对照组(P<0.05);观察组总有效率94.12%(32/34)高于对照组的73.53%(25/34)(P<0.05)。结论采用针刺治疗支气管哮喘可以改善患者的肺功能,提高治疗总有效率。

Clinical research of acupoint application for "treatment of winterdisease in summer" used to prevent and treat bronchial asthma inchildren

OBJECTIVE:To preliminarily analyze key factors influencing curative effect through clinical observations of acupoint application for "treatment of win-ter disease in summer" used to prevent and treat bronchial asthma in children.METHODS:In an observational study and prospective cohort study,we observed children in remission of asthma at three class Ⅲ grade A TCM hospitals in Liaoning,Hubei,and Chengdu.RESULTS:A total of 609 children conformed to diagnostic and inclusive standards for remission of bronchial asthma.Through follow-up visits,we observed their skin reactions and the time and chance of treatment with different therapies in the three hospitals;we also compared and analyzed different drugs,acupoints,and preparations.We found that the key Chinese drugs were Bai Jie Zi(Semen Sinapis Albae) and Yian Hu Suo(Rhizoma Corydalis);the key acupoints were Feishu(BL 13),Gaohuang(BL 43),Dingchuan(EX-B1),Tiantu(CV 22),and Shanzhong(CV 17);and the best preparation was a mixture of drugs,ginger juice,and musk.Acupoint application was practiced on the hottest days of summer and the coldest days of winter for 0.5 to 2 h with the lowest rate of asthma relapse.CONCLUSIONS:The present data analysis shows that the curative effect of acupoint application for "treatment of winter disease in summer" may be influenced by recipes of Chinese drugs,preparations,prescriptions of acupoints,chance,time,and skin reactions.A curative effect is the result of the comprehensive action of these factors.

中成药联合吸入疗法治疗儿童支气管哮喘的网状Meta分析

【目的】基于网状Meta分析评价中成药联合吸入疗法对儿童支气管哮喘的疗效及安全性。【方法】计算机检索中国期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、万方医学数据库(Wanfang Data)、维普信息资源系统(VIP)、Embase、PubMed、Web of Science等数据库中收录的中成药联合吸入疗法治疗儿童支气管哮喘的临床随机对照试验,应用Stata14对数据进行网状Meta分析。【结果】最终纳入28项研究,包括7种中成药,分别为寒喘祖帕颗粒、槐杞黄颗粒、痰热清注射液、小儿肺热咳喘颗粒、喘可治注射液、玉屏风颗粒、珠贝定喘丸。网状Meta分析结果显示,在提高总有效率方面,优选概率排名曲线(surface under the cumulative ranking curve,SUCRA)的概率排序居前3位的依次为痰热清注射液联合吸入疗法、喘可治注射液联合吸入疗法、珠贝定喘丸联合吸入疗法;改善肺功能指标呼气峰值流速(peak expiratory flow,PEF)、第1秒用力呼气容积(forced expiratory volume at one second,FEV1)、FEV1与用力肺活量(forced vital capacity,FVC)的比值(FEV1/FVC)最优的干预措施分别为痰热清注射液联合吸入疗法、寒喘祖帕颗粒联合吸入疗法、珠贝定喘丸联合吸入疗法;对不良反应发生率的SUCRA概率排序的分析结果显示,小儿肺热咳喘颗粒联合吸入疗法可能为副作用最小的干预措施,珠贝定喘丸联合吸入疗法可能为副作用较大的干预措施。【结论】中成药联合吸入疗法较单纯吸入疗法可提高小儿支气管哮喘的有效率及改善肺功能指标,且安全性较好。

Influence of Acupoint Application Therapy on Biochemical Indexes of Asthma Patients in Remission Period

Objective： To observe the influence of acupoint application therapy on serum eosinophilic granulocyte cationic protein （ECP）, 6 keto prostaglandin F 1 （6-keto-PGF 1） and thromboxane B2 （TXB2）. Methods： 300 cases of asthma out-patients in a remission period were divided into a treatment group （150 cases） and a control group （150 cases）. The control group was given the basic treatment, and the treatment group was given external application on the acupoints in July and December every year, as well as the basic treatment of the control group, with continuous treatment for 2 years as one course. ECP, 6-keto-PGF 1, and TXB2 were checked every year in the patients of the two groups, and an Asthma Control Test Table was filled in for comparative analysis. Results： After the external application on the acupoints, the frequency of seizures, dyspnea and frequency of medication administration of the patients had been more reduced than those in the control group, indicating that the levels of ECP in inflammation of air passage and of 6-eto-GF 1 and TXB2 were obviously improved （P〈0.05）. Conclusion： The herbal application on the acupoints is effective and positively influential to the improvement of the symptoms in the asthma patients and to ECP, 6-keto-PGF 1, and TXB2 remarkably.

针刺治疗支气管哮喘急性发作临床观察

目的 探讨中医针刺治疗支气管哮喘急性发作的效果及对患者肺功能的影响。方法 选择2020年2月—2021年5月南昌市第一医院收治的支气管哮喘急性发作患者106例作为对象,随机分为对照组(53例)和观察组(53例)。对照组采用药物治疗,观察组在对照组基础上行中医针刺治疗,比较2组患者的治疗效果。结果 治疗后,观察组各项症状积分均高于对照组,各项肺功能指标均优于对照组,气流受限各项指标亦均优于对照组,差异均有统计学意义(P<0.05);观察组白细胞介素-4(IL-4)水平低于对照组,干扰素-γ(INF-γ)水平高于对照组(P<0.05)。结论 支气管哮喘急性发作患者加用针刺治疗,可以更加有效地缓解临床症状,提高机体免疫能力,从而改善肺功能,具有较好的治疗效果,值得推广应用。

Clinical observation on acupoint injection of Chuankezhi injection plus acupoint sticking in treating bronchial asthma

Objective: To observe the clinical efficacy of acupoint injection of Chuankezhi plus acupoint sticking treatment for bronchial asthma, and provide clinical evidence for the synergy of the two therapies, and explore their synergistic mechanism. Methods: A total of 70 patients were randomized into an acupoint injection plus sticking group and an acupiont sticking group by the random number table, with 35 cases in each group. The treatment took place in July and August. The acupoint injection plus sticking group was treated with acupoint injection and acupiont sticking, while the acupiont sticking group was treated only with acupiont sticking therapy. The treatment course was 4 weeks. After the treatment, the scores of symptom scale in the two groups before treatment, 3 months and 6 months after the treatment were observed. Results: During the treatment, there were 5 dropouts in the acupoint injection plus sticking group with 30 cases remained, and 4 dropouts in the acupiont sticking group with 31 cases remained. Before the treatment, there was no significant difference in the total scores of symptom scale between the two groups. Three months after the treatment, the total scores of symptom scale of both groups were lower than those before treatment, and the intra-group differences were statistically significant (bothP<0.05). In the inter-group comparison, there was no significant difference in the difference values of the scores before treatment and 3 months after treatment (P>0.05). Six months after the treatment, the total scores of symptom scale in both groups were lower than those before treatment, and the intra-group differences were statistically significant (bothP<0.05), so were the differences in the difference values of the scores before treatment and 6 months after treatment (bothP<0.05). Conclusion: Acupoint injection of Chuankezhi plus acupoint sticking or acupoint sticking alone both can improve the symptoms of patients with bronchial asthma. Acupoint injection of Chuankezhi plus acupoint sticking has a higher total effective rate than single acupoint sticking therapy.

Clinical study of optimizing acupoint combining in treatment of bronchial asthma with acupoint application

Objective:To observe the therapeutic efficacy of acupoint application at different groups of acupoints in treating bronchial asthma in remission stage.Methods:A total of 120 patients with bronchial asthma in remission stage were recruited and divided by the random number table method into acupoint application group 1,acupoint application group 2 and acupoint application group 3,with 40 cases in each group.In all the three groups,Tiantu(CV 22),Dazhui(GV 14)and Feishu(BL 13)were selected,with Dingchuan(EX-B 1)added in acupoint application group 1,Shenshu(BL 23)added in acupoint application group 2,and Gaohuang(BL 43)added in acupoint application group 3.Before intervention,one month and 3 months after intervention,clinical symptoms,peak expiratory flow(PEF)and forced expiratory volume in 1 second percentage of predicted value(FEV1%)of the three groups were observed,and their clinical efficacies were evaluated.Results:Comparing the therapeutic efficacy regarding traditional Chinese medicine symptoms and signs,after 1-month treatment,the total effective rate was 87.5%in acupoint application group 1,versus 62.5%in acupoint application group 2 and 55.0%in acupoint application group 3,and the between-group differences were statistically significant.After 3-month treatment,the total effective rate was 95.0%in acupoint application group 1,versus 70.0%in acupoint application group 2 and 65.0%in acupoint application group 3,and the between-group differences were statistically significant.After intervention,the three groups all showed significant improvements in pulmonary function with statistical significance;among the three groups,the improvement in acupoint application group 1 was more significant than that in the other two groups.Conclusion:Tiantu(CV 22),Dazhui(GV 14)and Feishu(BL 13)as basic prescription plus Dingchuan(EX-B 1)can improve symptoms of bronchial asthma in remission stage,and it works better in improving pulmonary function than the basic prescription plus Shenshu(BL 23)or Gaohuang(BL 43).